ART signs GE

Article

GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D

GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D of therapeutic and diagnostic drugs. The system is an optical fluorescence molecular imaging device designed to help pharmaceutical companies and research laboratories better understand disease and shorten the development cycle for new drugs. The technology is based on ART's proprietary time domain optical imaging technology, which noninvasively images tissue to reveal the biological distribution and concentration of fluorescence-labeled markers. GE holds an equity stake in the firm and is advising staff there on the development of clinical products based on the optical technology (SCAN 11/6/02).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.